JP2020501510A - 目の表面で使用するためのアンカードメインを含む繋留タンパク質に基づく薬物 - Google Patents

目の表面で使用するためのアンカードメインを含む繋留タンパク質に基づく薬物 Download PDF

Info

Publication number
JP2020501510A
JP2020501510A JP2019515416A JP2019515416A JP2020501510A JP 2020501510 A JP2020501510 A JP 2020501510A JP 2019515416 A JP2019515416 A JP 2019515416A JP 2019515416 A JP2019515416 A JP 2019515416A JP 2020501510 A JP2020501510 A JP 2020501510A
Authority
JP
Japan
Prior art keywords
polypeptide
eye
anchor domain
binding
tnfα
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019515416A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020501510A5 (https=
Inventor
ロバート マイケル クイーン シャンクス，
ロバート マイケル クイーン シャンクス，
ジェス ケー． クラーランド，
ジェス ケー． クラーランド，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Publication of JP2020501510A publication Critical patent/JP2020501510A/ja
Publication of JP2020501510A5 publication Critical patent/JP2020501510A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C07K14/42—Lectins, e.g. concanavalin, phytohaemagglutinin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24003—Microbial collagenase (3.4.24.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2019515416A 2016-09-20 2017-09-19 目の表面で使用するためのアンカードメインを含む繋留タンパク質に基づく薬物 Pending JP2020501510A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662396958P 2016-09-20 2016-09-20
US62/396,958 2016-09-20
PCT/US2017/052288 WO2018057522A1 (en) 2016-09-20 2017-09-19 Harnessing protein-based drugs comprising an anchor domain for use on the ocular surface

Publications (2)

Publication Number Publication Date
JP2020501510A true JP2020501510A (ja) 2020-01-23
JP2020501510A5 JP2020501510A5 (https=) 2020-10-08

Family

ID=61690642

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019515416A Pending JP2020501510A (ja) 2016-09-20 2017-09-19 目の表面で使用するためのアンカードメインを含む繋留タンパク質に基づく薬物

Country Status (5)

Country Link
US (1) US20200331984A1 (https=)
EP (1) EP3516063A4 (https=)
JP (1) JP2020501510A (https=)
AU (1) AU2017330565A1 (https=)
WO (1) WO2018057522A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021514661A (ja) * 2018-03-05 2021-06-17 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ サイトカインに連結させたｅｃｍ親和性ペプチドを用いてがんを処置するための方法および組成物
JP2023530106A (ja) * 2020-06-12 2023-07-13 モナシュ ユニバーシティ 細胞外マトリックスに結合するＩＬ－１受容体アンタゴニスト（ＩＬ－１Ｒａ）融合タンパク質

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019173829A1 (en) 2018-03-09 2019-09-12 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Delivering biological drugs to tissues
US20230312685A1 (en) * 2019-10-25 2023-10-05 Mayo Foundation For Medical Education And Research Bi-Peptide with Affinity to Extracellular Matrix Proteins or Cells and to Growth Factors for Tissue Healing and Regeneration
WO2022082070A1 (en) * 2020-10-15 2022-04-21 Northeastern University Engineered cells for increased collagen production
US20250302913A1 (en) * 2022-05-06 2025-10-02 The Regents Of The University Of California Lacripep promotes neuroregeneration and maintains epithelial progenitor cell identity
EP4615482A2 (en) * 2022-11-08 2025-09-17 Nextcure, Inc. Immune checkpoint inhibitor and extracellular matrix component binder combination therapy and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014506893A (ja) * 2011-02-15 2014-03-20 バキシオン セラピューティクス，インコーポレイテッド 抗体およびＦｃ含有標的化分子に基づく生理活性分子の標的送達のための細菌ミニ細胞による治療用組成物および方法
JP2015522590A (ja) * 2012-06-25 2015-08-06 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 標的化治療薬
JP2016500323A (ja) * 2012-12-19 2016-01-12 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ 液体ディスペンサのための案内デバイス
JP2016053039A (ja) * 2009-07-29 2016-04-14 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ ＴＧＦ−β受容体ＲＩＩを結合するリガンド

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387663B1 (en) * 1998-07-31 2002-05-14 University Of Southern California Targeting pharmaceutical agents to injured tissues
US20040224010A1 (en) * 2002-11-15 2004-11-11 Optime Therapeutics, Inc. Ophthalmic liposome compositions and uses thereof
WO2014089267A1 (en) * 2012-12-05 2014-06-12 Eleven Biotherapeutics, Inc. Galectin-3 fusion proteins
HRP20251426T1 (hr) * 2013-05-06 2026-01-02 Scholar Rock, Inc. Sastavi i postupci za modulaciju faktora rasta
WO2014197485A1 (en) * 2013-06-03 2014-12-11 Ansun Biopharma, Inc. Anti-viral therapeutic for infection of the eye

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016053039A (ja) * 2009-07-29 2016-04-14 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ ＴＧＦ−β受容体ＲＩＩを結合するリガンド
JP2014506893A (ja) * 2011-02-15 2014-03-20 バキシオン セラピューティクス，インコーポレイテッド 抗体およびＦｃ含有標的化分子に基づく生理活性分子の標的送達のための細菌ミニ細胞による治療用組成物および方法
JP2015522590A (ja) * 2012-06-25 2015-08-06 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 標的化治療薬
JP2016500323A (ja) * 2012-12-19 2016-01-12 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ 液体ディスペンサのための案内デバイス

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
GRAEFE'S ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, vol. Vol.228, No.6, pp.528-532, JPN7022001878, 1990, ISSN: 0004945389 *
INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. Vol.138, p.175-183, JPN6021024121, 1996, ISSN: 0004945384 *
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. Vol.52, p.7090-7097, JPN6021024125, 2011, ISSN: 0004945386 *
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. Vol.54, p.7557-7566, JPN6021024122, 2013, ISSN: 0004945387 *
THE HISTOCHEMICAL JOURNAL, vol. Vol.26, No.10, pp.787-798, JPN6022015257, 1994, ISSN: 0004945388 *
電子顕微鏡, vol. Vol.22, No.1, p.25-33, JPN6021024127, 1987, ISSN: 0004945385 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021514661A (ja) * 2018-03-05 2021-06-17 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ サイトカインに連結させたｅｃｍ親和性ペプチドを用いてがんを処置するための方法および組成物
JP2023530106A (ja) * 2020-06-12 2023-07-13 モナシュ ユニバーシティ 細胞外マトリックスに結合するＩＬ－１受容体アンタゴニスト（ＩＬ－１Ｒａ）融合タンパク質

Also Published As

Publication number Publication date
EP3516063A1 (en) 2019-07-31
EP3516063A4 (en) 2020-05-13
WO2018057522A1 (en) 2018-03-29
US20200331984A1 (en) 2020-10-22
AU2017330565A1 (en) 2019-04-11

Similar Documents

Publication Publication Date Title
JP2020501510A (ja) 目の表面で使用するためのアンカードメインを含む繋留タンパク質に基づく薬物
US10940179B2 (en) Therapeutic compositions for the treatment of dry eye disease
JP7725540B2 (ja) 眼の感染症および疾患を処置するための組成物および方法
US11529389B2 (en) Delivering biological drugs to tissues
US11198714B2 (en) Synthetic truncated norrin protein
CN113645994A (zh) 使用色素上皮衍生因子(pedf)治疗疾病的方法
KR20220018963A (ko) 치료 방법
JP2023509880A (ja) 加齢黄斑変性の治療における融合タンパク質の使用
Bai et al. During glaucoma, α2-macroglobulin accumulates in aqueous humor and binds to nerve growth factor, neutralizing neuroprotection
JP2020536065A (ja) 興奮性神経毒性に関連した損傷の治療用ペプチド組成物
ES3025657T3 (en) Tsg6 polypeptide fragment for dry eye disease
US20150307619A1 (en) Use of C-C Chemokine Receptor Type 7 (CCR7) Inhibitors
KR20220051791A (ko) Fas 신호전달 억제용 펩타이드를 포함하는 황반변성 예방 또는 치료용 조성물
US20230279086A1 (en) Suppression of uveitis by single domain antibody
CN111686241A (zh) Il-38蛋白在制备治疗眼科疾病的药物中的应用
US20250312412A1 (en) Methods for treating dry eye disease
TW202506704A (zh) 具有改善乾眼症活性的新型胜肽及包括其之藥物組合物
Dabouz Neuro-immune interactions in age-related macular degeneration: implications for future therapeutics
Ben-Arzi et al. Anti-VEGF Agents Clearance Through the Aqueous Outflow Pathway in a Rat Model
ES3041181T3 (en) Agents that inhibit the binding of cfh to cd11b/cd18 and uses thereof
Fernández et al. Case Report Med. 2012; 2012: 897097. doi: 10.1155/2012/897097. Epub 2012 Oct 30. Verteporfin photodynamic therapy combined with intravitreal ranibizumab for polypoidal choroidal vasculopathy controversy concerning long-term followup.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200831

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200831

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210623

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210625

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210903

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220419

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220616

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221215